1. Home
  2. TCRX vs XBIT Comparison

TCRX vs XBIT Comparison

Compare TCRX & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.52

Market Cap

75.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCRX
XBIT
Founded
2018
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.6M
75.0M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
TCRX
XBIT
Price
$1.21
$2.52
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
1.2M
25.9K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
12.28
N/A
EPS
N/A
N/A
Revenue
$10,325,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$19.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
266.65
N/A
52 Week Low
$0.88
$2.09
52 Week High
$2.57
$3.61

Technical Indicators

Market Signals
Indicator
TCRX
XBIT
Relative Strength Index (RSI) 53.19 61.43
Support Level $0.93 $2.15
Resistance Level $1.21 $2.69
Average True Range (ATR) 0.10 0.07
MACD 0.02 0.02
Stochastic Oscillator 35.19 68.75

Price Performance

Historical Comparison
TCRX
XBIT

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: